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Abstract
Introduction. Guillain–Barre Syndrome (GBS) is an acute demyelinating polyneuropathy which can occur post-infection.
Criteria of diagnosis of GBS include areflexia with progressive bilateral weakness in arms and legs. GBS can lead to severe
respiratory and cardiac complications. The fatality rate can be up to 5% in patients, depending on the severity of the
symptoms. HIV can cause a range of neurological disorders including, on rare occasions, GBS. GBS can occur at any stage of
HIV infection, highlighting the complexity of diagnosis of GBS within HIV patients.
Case presentation. A 57 year old female with lumbar back pain radiating to the legs, poor mobility and tiredness, with
reports of a viral-like illness four days previously, was initially diagnosed with a lower respiratory tract infection and
discharged. Seventeen days later the patient was readmitted to hospital with progressive lower and upper limb weakness,
areflexia and sensory loss. She was diagnosed with GBS and was unexpectedly discovered to be HIV-positive. HIV avidity
was low indicating a recently acquired HIV infection. The patient was treated with intravenous immunoglobulin for five days
for the GBS and commenced antriretrovirals for HIV. The patient was discharge from hospital 53 days after admission with
walking aids and regular physiotherapy follow-up.
Conclusion. This case highlighted the need for all clinicians to be aware that patients with symptoms of GBS, regardless of
clinical history should be offered an HIV test. GBS can be the first sign a patient is HIV-positive.
INTRODUCTION
Guillain–Barre syndrome (GBS) is an acute inflammatory
demyelinating polyneuropathy which has an incidence rate
in Europe of less than 2 cases per 100 000 [1]. It is an auto-
immune disease which often occurs post-infection. Sixty
percent of patients recall gastroenteritis or a respiratory
infection within 6weeks prior to GBS symptoms [1]. Diag-
nostic criteria include areflexia with progressive bilateral
weakness in the arms and legs [2] and this can be compli-
cated by severe respiratory and cardiac complications. The
fatality rate is 5 and 20% develop long term neurological
sequelae [3]. Several viral infections have been associated
with GBS including cytomegalovirus (CMV), Hepatitis E
virus (HEV) and Zika virus [4–6]. GBS can also occur with
both acute and long-standing HIV infections [7]. The Brit-
ish HIV Association (BHIVA) guidelines state that a patient
presenting with GBS should be screened for HIV [8].
The case presented highlights a patient who was admitted to
hospital with pain and bilateral limb weakness and who was
discharged five days later without virological screening. It
was on re-admission to hospital with progressive symptoms
that the patient was found to be HIV-positive. This case
highlights the importance of considering viral diagnoses,
including HIV, in patients with GBS, including those with
no apparent blood-borne virus risk factors.
CASE REPORT
A 57 year old female was admitted to hospital with lumbar
back pain radiating to the legs, poor mobility and tiredness.
She reported a viral-like illness four days prior to admission
characterised by mild cough, diarrhoea and vomiting. Blood
tests indicated: C-reactive protein 19mg l 1, sodium level
120mmol l 1, white blood cell count 12.1109 l 1 and
platelet count 387109 l 1. A CT scan of brain, chest, abdo-
men and pelvis revealed pulmonary nodules likely to be
inflammatory or infective in nature and was otherwise unre-
markable. The initial diagnosis was lower respiratory tract
infection (LRTI) with hyponatraemia. No neurological
abnormalities were documented and muscle weakness was
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attributed to infection and electrolyte imbalance. The differ-
ential diagnosis of hyponatraemia was attributed to LRTI or
eplerenone which the patient had been prescribed following
a myocardial infarction 9months previously. Due to a his-
tory of alcohol excess, the patient was started on Pabrinex
and amoxicillin and the eplerenone was discontinued. Her
sodium level improved and she was discharged 5 days later
with a follow-up appointment.
Seventeen days later the patient was re-admitted to hospital
with progressive lower limb weakness, new hand weakness
and sensory loss in the hands and feet. On examination
there was evidence of reduced power in the upper and lower
limbs with areflexia and sensory loss in a glove and stocking
distribution.
INVESTIGATIONS
A lumbar puncture revealed a raised protein [1.69 g l 1
(range 0.10–0.50 g l 1)], pleocytosis [white blood cell
count (WBC) was 39 cells mm 3 with 90% lymphocytes
and 10% polymorphs] and low glucose [2.4 (range 2.5–
4.5mmol l 1)]. Serum and cerebrospinal fluid (CSF)
revealed evidence of oligoclonal bands.
Nerve conduction studies showed mixed sensory motor pol-
yneuropathy with ongoing axonal loss affecting both the
upper and lower limb muscles. There were no demyelinat-
ing features. The ganglioside antibody screen was normal.
An MRI brain showed small vessel disease only.
Virological investigations found the patient to be HIV-1
positive by the Abbott Architect Ab/Ag combination assay,
BioMeriuex miniVidas and the Bio-Rad Geenius reader
HIV 1/2 conformational test. The HIV viral load using the
Abbott RealTime HIV-1 was 195 328 copies ml 1. Using an
in-house avidity assay the HIV avidity was low (20%) indi-
cating that the patient had a recent infection within the past
three to four months [9]. The CD4 count was 730 cells
mm 3. The patient was HBV surface antigen-, HBV core
IgG-, HCV antibody- and syphilis-negative. Toxoplasma
IgG was equivocal and IgM was negative. There was no evi-
dence of Salmonella species, Shigella, E.coli O157, Campylo-
bacter, Clostridium difficle or Cryptosporidium oocysts in
faecal samples. The cerebrospinal fluid was negative by PCR
for HSV1, HSV2, VZV, enterovirus, parechovirus, JC poly-
omavirus, CMV, EBV, HHV6, meningococcus, pneumococ-
cus and Haemophilus influenzae. The patient was negative
for Cryptococcus neoformans in both the CSF and blood.
Using an in-house real-time PCR assay, the CSF was found
to be HIV RNA-positive. The HIV RNA pol gene was
sequenced and found to be a complex recombinant form
(GenBank accession number MF372642).
DIAGNOSIS
The final diagnosis was HIV seroconversion illness with
bilateral sensory and motor axonal neuropathy of the upper
and lower limbs. As the low HIV avidity result, CD4 count
and clinical manifestations indicated that the patient had
been recently infected with HIV, and the only risk was sex-
ual contact with her long-term partner (who had spent long
periods of time working in sub-Saharan Africa), he was
tested for HIV and found to be HIV-1 positive with a CD4
count 144 cells mm 3 and HIV viral load of 208 000 copies
ml 1. The HIV avidity result was high (99%) indicating a
long-standing infection. Based on the HIV pol gene, the
HIV subtype was found to be a complex recombinant form
(GenBank accession number MF372643). Although both
patient and partner had complex recombinant forms of
HIV, when the sequences were aligned there were only
five main base pair differences between the two sequences
(Fig. S1, available in the online Supplementary Material).
TREATMENT
The patient was commenced on intravenous immunoglobu-
lins (IVIG) at 400mg kg 1 day 1 for 5 days and started on
Triumeq, a once daily tablet combination of the antiretrovi-
rals abacavir, lamivudine and dolutegravir. The HIV viral
load dropped to <40 detected copies ml 1 twomonths after
therapy was commenced.
OUTCOME AND FOLLOW-UP
The patient was discharged from hospital 53 days later with
improved mobility but still requiring the use of walking
aids. The patient continues to be compliant with her antire-
trovirals and is now attending regular physiotherapy and
outpatient clinic follow up.
DISCUSSION
HIV can cause a range of neurological disorders affecting
cognitive function and the peripheral nervous system [10–
12]. Patients with GBS need to be offered testing for HIV as
this syndrome can often be the first sign a patient is HIV-
positive [13, 14]. Clinical signs of GBS are similar for
patients regardless of their HIV status [13, 15]. Lower limb
paraesthesia and bilateral lower limb weakness with are-
flexia have been reported in HIV-positive patients with GBS
[16–20]. Flu-like symptoms, fever, maculopapular rash and
gastrointestinal symptoms prior to onset of GBS have been
reported in some of these patients [16, 17, 19]. The variety
of symptoms reported with GBS following HIV seroconver-
sion, highlight its complexity. Quadriparesis occurred in
one patient, with improvement following IVIG treatment
[18]. In two other reported cases, one of which was fatal,
both patients progressed to weakness in all limbs as well as
dyspnoea, dysarthria and facial palsy [16, 17]. GBS has also
been documented in chronic HIV infection [19, 20]. In one
chronic case the patient had stopped antiretroviral therapy
three months before limb weakness began [20]. Another
patient with chronic HIV, was reported to have GBS symp-
toms two months after commencement of antiretroviral
therapy [19].
Molecular mimicry and antiganglioside antibodies are con-
sidered to be involved in the pathogenesis of GBS following
infection [21]. The history, examination and clinical disease
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course of HIV-associated GBS resembles non-HIV-related
GBS. Nerve conduction studies reveal similar patterns to
those of HIV-negative patients. Elevated CSF protein is
found in GBS of any cause, while WBC pleocytosis is seen
more frequently in HIV-positive patients [14]. The patient
in this report had both elevated protein and WBC pleocyto-
sis in her CSF.
HIV virus was detected in the CSF fluid of our patient. Cen-
tral nervous system (CNS) inflammation and detection of
HIV RNA in the CSF can occur in the early stages of acute
infection [22–24]. HIV can have both direct and indirect
neurotoxic effects on the CNS and peripheral nervous sys-
tem [25–27]. HIV can continue to maintain a presence in
the CNS even under antiretroviral therapy [28, 29]. The
patient in this case was commenced on abacavir, lamivudine
and dolutegravir. All three of these antiretrovirals have been
shown to effectively reduce HIV RNA levels in the CSF
[30, 31].
A higher frequency of GBS has been found in African HIV-
positive patients [19]. The partner of this particular patient
had been working in Africa and had been engaged in high-
risk sexual activity. The HIV avidity result for the partner
indicated a chronic infection which, given the recombinant
HIV subtype, is likely to have been acquired in Africa.
There is insufficient evidence on long-term outcomes in
HIV-positive GBS patients. It has been suggested that com-
pared with HIV-negative individuals HIV-related GBS may
be related to more frequent recurrent episodes [18].
In some circumstances avidity assays can generate false
recent results [32]. This can occur in HIV avidity assays
when the HIV viral load is less than 1000 copiesml 1, the
patient CD4 count is less than 250 cells mm 3 or the
patient is on antiretroviral therapy prior to avidity testing
[33]. The patient in this case did not have any factors that
would contribute to a false low level avidity result. This is
the first case, to our knowledge, where a recent HIV infec-
tion has been confirmed by HIV avidity in a patient
with GBS.
This patient did not consider herself to be at high risk for
HIV infection. Patients with GBS should be tested for HIV
and this syndrome can often be the first sign a patient is
HIV-positive [18, 20]. This case highlights the importance
of testing all patients with GBS-like and neurological symp-
toms for HIV regardless of risk factors.
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